Tandem Diabetes Care, Inc. (TNDM) posted a third-quarter 2024 loss of 36 cents per share compared with the year-ago quarter’s reported loss of 38 cents. The figure beat the Zacks Consensus Estimate of a loss of 43 cents per share.On a GAAP basis, the loss was 35 cents per share compared with the year-ago loss of 51 cents.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Following the earnings announcement, TNDM stock fell 2% in aftermarket trading yesterday. TNDM’s Q3 RevenuesGAAP reven ...

For the quarter ended September 2024, Tandem Diabetes Care, Inc. (TNDM) reported revenue of $243.97 million, up 31.4% over the same period last year. EPS came in at -$0.36, compared to -$0.38 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $223.33 million, representing a surprise of +9.24%. The company delivered an EPS surprise of +16.28%, with the consensus EPS estimate being -$0.43.While investors closely watch year-over-year changes in headline numbers -- revenue ...

Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.38 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 16.28%. A quarter ago, it was expected that this company would post a loss of $0.54 per share when it actually produced a loss of $0.47, delivering a surprise of 12.96%.Over the last four quarters, the company h ...

Exhibit 99.1 FOR IMMEDIATE RELEASE Third Quarter 2024 Highlights Media Contact: 858-366-6900 media@tandemdiabetes.com Investor Contact: 858-366-6900 IR@tandemdiabetes.com Tandem Diabetes Care Announces Third Quarter 2024 Financial Results and Increases Full Year 2024 Sales Guidance San Diego, November 6, 2024 - Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2024 and increased sales ...

Core Viewpoint - Tandem Diabetes Care, Inc. (TNDM) has experienced a significant decline of 21.7% over the past four weeks, but it is now positioned for a potential trend reversal as it enters oversold territory, with analysts predicting better earnings than previously expected [1]. Group 1: Stock Performance and Indicators - TNDM's Relative Strength Index (RSI) reading is at 29.87, indicating that the heavy selling pressure may be exhausting, suggesting a possible bounce back towards previous supply and demand equilibrium [3]. - The stock is considered oversold when its RSI falls below 30, which is a common threshold for identifying potential price reversals [2]. Group 2: Earnings Estimates and Analyst Consensus - There is strong consensus among sell-side analysts that earnings estimates for TNDM have increased by 0.1% over the last 30 days, indicating a positive outlook for the company's financial performance [4]. - TNDM holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a near-term turnaround [4].

Tandem Diabetes Care (TNDM) has achieved a significant milestone by gaining approval for the use of its t:slim X2 insulin pump with Eli Lilly's ultra-rapid acting insulin, Lyumjev, in the European Union (EU). The compatibility with Lyumjev offers new possibilities in the insulin delivery landscape, enhancing the efficacy of Tandem's automated insulin delivery (AID) systems. This latest development strengthens Tandem's position in the diabetes technology market and enhances its offerings for individuals with ...

Tandem Diabetes (TNDM) is gaining from continued product innovations. Yet, ongoing macroeconomic challenges and tough competition pose challenges. The stock carries a Zacks Rank #3 (Hold) currently. Factors Driving TNDM Stock Tandem Diabetes seeks to grow its business through the acquisition of products or technologies or investments in businesses. Last year, it acquired Swiss-based AMF Medical SA — the developer of the Sigi Patch Pump. The company's speed-to-market with Continuous Glucose Monitoring (CGM) ...

Tandem Diabetes Care, Inc.'s (TNDM) flagship t:slim X2 insulin pump with Control-IQ automated insulin delivery (AID) technology is now certified for use with Eli Lilly and Company's (LLY) Lyumjev (insulin lispro-aabc injection) ultra-rapid acting insulin in the European Union (EU). The development follows a clinical study that reported high satisfaction and quality of life benefits by pairing Lyumjev with Control-IQ technology. Ultra-rapid acting insulin is a popular choice for people living with diabetes b ...

At a stroke, it's got a product authorized for a specific use in 27 countries. Tandem Diabetes Care (TNDM 4.25%) had some encouraging news to report on the regulatory front Thursday, and after it hit the headlines investors piled into the stock. At the end of the day the highly specialized healthcare company's share price had risen in excess of 4%, good enough to top the 1.7% rise of the benchmark S&P 500 index. Crucial approval granted Tandem announced Thursday morning that it had won an important approval ...

Tandem Diabetes Care, Inc.'s (TNDM) growth is backed by its impressive range of new products. The flourishing diabetes market provides a favorable opportunity for the company's growth. However, concerns loom over Tandem Diabetes' substantial reliance on insulin pumps and the adverse impact of macroeconomic challenges. In the past year, this Zacks Rank #3 (Hold) company has surged 56.2% compared with 10.9% growth of the industry and a 24.9% rise of the S&P 500 composite. The renowned medical device company h ...